Levosimendan

• UNSPSC Description:

  Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

• Target Antigen:

  Autophagy; Phosphodiesterase (PDE); Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Levosimendan.html

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C1C[C@@H](C)C(C2=CC=C(N/N=C(C#N)/C#N)C=C2)=NN1

• Molecular Weight:

  280.28

• References & Citations:

  [1]Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245.|[2]Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7.|[3]Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  141505-33-1